The immune heterogeneity between pulmonary adenocarcinoma and squamous cell carcinoma: a comprehensive analysis based on lncRNA model

ABSTRACT: Adenocarcinoma (AD) and squamous carcinoma (SCC) are major types of lung cancer. Although they both belong to non-small cell lung cancer (NSCLC), the differences in clinical prognosis and molecular mechanism between them are remarkable. Recently, numerous studies proved that immune status of carcinoma patients influence deeply the clinical outcome. Based on the theory of “Immune edit”, many immunotherapies come out and tremendously extended the life of the patients. Thus, research on immune status is significant and essential. Our study aims to select specific lncRNAs which control the key immune-related genes to construct the risk model for AD and SCC respectively and the patients were divided into high- and low-risk groups based on risk score. The prognostic significance of risk score was validated by our own cohorts. Besides, The GSEA analysis suggested that immune response or process of AD patients in high-risk group was weaken while the situation is opposite for SCC cohort. The evaluation of immune infiltration reveled that the infiltrating degree of dendritic cell (DC cell) might be the important change for AD patients. In addition, the prediction of response to immune checkpoint inhibitors (ICIs) treatment, based on T cell immune dysfunction and exclusion (TIDE) and immunophenoscore (IPS), indicated that the reasons for the deterioration of the immune microenvironment were T cell exclusion in AD patients and T cell dysfunction in SCC patients and the high-risk patients with SCC might benefit from ICIs treatment. Furthermore, the prediction of downstream targets via The Cancer Proteome Atlas (TCPA) database and RNA-seq analysis based on transferred lung cancer cell line indicated that lINC00996 was potential to become the therapeutic target for AD patients.

ORGANISM(S): Homo sapiens

PROVIDER: GSE179934 | GEO | 2021/08/01

REPOSITORIES: GEO